Hikma CEO Siggi Olafsson says the firm is in a position to execute a major deal if the right opportunity comes along, but is not under any pressure to pursue M&A for its own sake.
Hikma is feeling no pressure to execute a major merger or acquisition, while at the same being in a favorable financial position that makes it ready to pounce on a deal if the right opportunity arises, according to CEO Siggi Olafsson.
In the first part of this exclusive interview with Generics Bulletin, Olafsson talked about how Hikma’s broad US injectables portfolio...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
